Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.76 |
| ▸ | NPC1 | O15118 | 11/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.51 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12310125 | 0.87 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL15214321 | 0.87 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL27181403 | 0.87 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL14580374 | 0.87 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL822378 | 0.87 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL21114821 | 0.82 | PTPN1 (0.67) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL21185831 | 0.82 | RAB9A (0.88) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL17066707 | 0.82 | RAB9A (0.88) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL15214314 | 0.82 | RAB9A (0.88) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL25491824 | 0.82 | RAB9A (0.88) | RAB9ANPC1SMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173287-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-11766420-B2 | Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease | Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. (CN) | 2023-09-26 | — | — | US | disclosed |
| EP-3290525-B1 | METHOD FOR SCREENING DRUG AND THERAPEUTIC TARGET USED FOR TREATING ALZHEIMER'S DISEASE | JIANGSU NUO BETA PHARMACEUTICAL TECH CO LTD (CN) | 2022-02-23 | — | — | EP | disclosed |
| US-11236378-B2 | Method for screening drug and therapeutic targets used for treating Alzheimer's disease | Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20190314321-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190211371-A1 | Method For Screening Drug And Therapeutic Targets Used For Treating Alzheimer's Disease | JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-3290514-A1 | APPLICATION OF PI4KIII PROTEIN AND RELATED MEMBRANE PROTEIN COMPLEX IN TREATING ALZHEIMER'S DISEASE | Jiangsu Nuo-Beta Pharmaceutical Technology Co., Ltd. (CN) | 2018-03-07 | — | — | EP | disclosed |
| EP-3290525-A1 | METHOD FOR SCREENING DRUG AND THERAPEUTIC TARGET USED FOR TREATING ALZHEIMER'S DISEASE | Jiangsu Nuo-Beta Pharmaceutical Technology Co., Ltd. (CN) | 2018-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314321-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | PI4K2A, PI4K2B, PIP4K2A | RAB9A 491/4885NPC1 3065/4885SMN1; SMN2 3090/4885 |
| US-11236378-B2 | Method for screening drug and therapeutic targets used for treating Alzheimer's disease | PSD, TBRG4, ACTR3 | RAB9A 478/4885NPC1 1606/4885SMN1; SMN2 3439/4885 |
| US-11766420-B2 | Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease | PI4K2A, PI4K2B, PIP4K2A | RAB9A 491/4885NPC1 3065/4885SMN1; SMN2 3090/4885 |
| US-20240173287-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | PI4K2A, PI4K2B, PIP4K2A | RAB9A 491/4885NPC1 3065/4885SMN1; SMN2 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.